Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02123498
Other study ID # ETDLPR2014
Secondary ID
Status Withdrawn
Phase Phase 4
First received April 23, 2014
Last updated September 22, 2016

Study information

Verified date April 2014
Source Loma Linda University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the relationship between ear fullness, pressure, and/or pain and laryngopharyngeal reflux, in order to focus medical therapy and improve therapeutic outcomes in this patient population.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- They complain of symptoms of ear fullness, ear pain, and/or ear pressure, either unilateral or bilateral

- They are willing to participate in the study.

- They are between the ages of 18 to 80

Exclusion Criteria:

- They have had major ear surgery (not including tympanostomy tubes)

- They have a medical condition that is another possible etiology of ear pain or acid reflux and may require additional medical or surgical intervention such as: Acute or chronic otitis externa, Chronic otitis media, Temporomandibular joint dysfunction, Upper aerodigestive track neoplasm, History of head/neck radiation therapy.

- They are pregnant. Proton pump inhibitors are a Category C drug with unknown pregnancy risks.

- They do not wish to participate in the study

- They are <18 or >80.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Omeprazole
40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
Ranitidine
300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
Pantoprazole
40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
Procedure:
24-Hour Diagnostic pH-Probe Test
Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
Laryngoscopy
Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.

Locations

Country Name City State
United States 11234 Anderson Street Loma Linda California
United States 1895 Orange Tree Lane, Suite 102 Redlands California

Sponsors (1)

Lead Sponsor Collaborator
Loma Linda University

Country where clinical trial is conducted

United States, 

References & Publications (7)

Barbero GJ. Gastroesophageal reflux and upper airway disease. Otolaryngol Clin North Am. 1996 Feb;29(1):27-38. — View Citation

Crapko M, Kerschner JE, Syring M, Johnston N. Role of extra-esophageal reflux in chronic otitis media with effusion. Laryngoscope. 2007 Aug;117(8):1419-23. — View Citation

Heavner SB, Hardy SM, White DR, Prazma J, Pillsbury HC 3rd. Transient inflammation and dysfunction of the eustachian tube secondary to multiple exposures of simulated gastroesophageal refluxant. Ann Otol Rhinol Laryngol. 2001 Oct;110(10):928-34. — View Citation

Mims JW. The impact of extra-esophageal reflux upon diseases of the upper respiratory tract. Curr Opin Otolaryngol Head Neck Surg. 2008 Jun;16(3):242-6. doi: 10.1097/MOO.0b013e3282fdc3d6. Review. — View Citation

Norman G, Llewellyn A, Harden M, Coatesworth A, Kimberling D, Schilder A, McDaid C. Systematic review of the limited evidence base for treatments of Eustachian tube dysfunction: a health technology assessment. Clin Otolaryngol. 2014 Feb;39(1):6-21. doi: 10.1111/coa.12220. Review. — View Citation

Schreiber S, Garten D, Sudhoff H. Pathophysiological mechanisms of extraesophageal reflux in otolaryngeal disorders. Eur Arch Otorhinolaryngol. 2009 Jan;266(1):17-24. doi: 10.1007/s00405-008-0770-1. Epub 2008 Aug 13. Review. — View Citation

Yazici ZM, Sari M, Uneri C, Midi A, Tugtepe H. Histologic changes in eustachian tube mucosa of rats after exposure to gastric reflux. Laryngoscope. 2008 May;118(5):849-53. doi: 10.1097/MLG.0b013e318164d0c0. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evidence of laryngopharyngeal reflux in patients complaining of ear fullness/pressure/pain Participants complaining of ear pain, ear fullness, or ear pain are diagnosed with laryngopharyngeal reflux via laryngoscope exam and measurement by diagnostic pH-probe test. 1 year No
See also
  Status Clinical Trial Phase
Recruiting NCT06205446 - Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction N/A
Completed NCT02552966 - Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin N/A
Completed NCT01450748 - Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux Phase 3
Recruiting NCT04827355 - Reflux Band in Laryngopharyngeal Reflux N/A
Not yet recruiting NCT03455803 - Effect of CPAP Therapy on LPR Among Patients With OSAS N/A
Withdrawn NCT02530879 - Comparison of Voice Therapy and Antireflex Therapy in LPR Phase 4
Completed NCT01854970 - Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux N/A
Completed NCT00321503 - Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR) N/A
Terminated NCT01317472 - The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux N/A
Completed NCT01880892 - Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy N/A
Completed NCT02183961 - Three Methods Used in the Diagnosis of EER in Children With OME N/A
Not yet recruiting NCT01328652 - Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Phase 4
Not yet recruiting NCT04383262 - Lexiva for the Treatment of LPR Phase 3
Recruiting NCT04984304 - Individualized Diagnosis and Treatment of Extraesophageal Reflux in Patients With Chronic Cough N/A
Withdrawn NCT03463395 - Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux N/A
Completed NCT00864396 - Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux Phase 1
Completed NCT03619811 - Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease N/A
Recruiting NCT05879029 - Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD Phase 4
Recruiting NCT05204303 - LPR Fluorescence Pilot
Terminated NCT01777854 - Anti-reflux Control to Decrease Post Tonsillectomy Pain Phase 4